Hollister Biosciences Inc. to Report Q3 2021 Financial Results on November 29, 2021

 Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") today announced it will release its third quarter fiscal year ended September 30 2021 after market close on Monday, November 29, 2021.

Following the release of its third quarter financial results, the Company will hold a conference call on Tuesday, November 30, 2021 at 4:00pm ET.

The live audio earnings conference call may be accessed online and by phone using the link: https://www.renmarkfinancial.com/events/third-quarter-2021-results-cse-holl- 2021-11-30-160000 . Investors may pre-register for the call by navigating to the same link provided. The conference call will be archived for replay and accessible at https://hollisterbiosciences.co/investors/ .

About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high- quality cannabis & hemp branded consumer products and white-labeling manufacturing. Our products are sold in 370 dispensaries across Arizona and California . Hollister Biosciences wholly-owned brand, Venom Extracts, is a category-leading brand that sold more than 4 million grams in 2020, accounting for up to 30% of category sales in Arizona.

Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA, birthplace of the "American Biker".

Website: www.hollisterbiosciences.co

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/hollister-biosciences-inc-to-report-q3-2021-financial-results-on-november-29-2021-301428801.html

SOURCE Hollister Biosciences Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/November2021/18/c7731.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Dried mushrooms in the center are surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain

On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as an alternative... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...
Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous... Keep Reading...

Interactive Chart

Latest Press Releases

Related News